7 March 2022 - Teva Pharmaceuticals announced today the launch of a first generic version of Revlimid (lenalidomide capsules), in 5 mg, 10 mg, 15 mg and 25 mg strengths, in the United States.

Teva’s Lenalidomide capsules are a prescription medicine used in adults for the treatment of (1) multiple myeloma in combination with the medicine dexamethasone, (2) certain myelodysplastic syndromes, and (3) mantle cell lymphoma following specific prior treatment.

Read Teva Pharmaceuticals press release